Tandem Diabetes Care (TNDM) Cash from Financing Activities (2013 - 2026)

Tandem Diabetes Care (TNDM) has 14 years of Cash from Financing Activities data on file, last reported at $274.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 5948.14% year-over-year to $274.2 million; the trailing twelve-month figure through Mar 2026 stood at $235.5 million (up 2476.93% YoY), and the FY2025 full-year result was -$43.4 million, down 618.31% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $274.2 million, up from $2.6 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $274.2 million in Q1 2026 and bottomed at -$39.7 million in Q2 2025.
• The 5-year median for Cash from Financing Activities is $2.3 million (2024), against an average of $15.3 million.
• The widest annual swing landed in 2025, when Cash from Financing Activities sank 1222.88%; it then jumped 5948.14% in 2026.
• A 5-year view of Cash from Financing Activities shows it stood at $6.1 million in 2022, then plunged by 57.1% to $2.6 million in 2023, then decreased by 12.04% to $2.3 million in 2024, then gained by 13.12% to $2.6 million in 2025, then surged by 10428.46% to $274.2 million in 2026.
• The last three Cash from Financing Activities figures came in at $274.2 million (Q1 2026), $2.6 million (Q4 2025), and -$1.6 million (Q3 2025), per Business Quant data.

Peer Comparison